{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["28(3)"],"submitter":["Riveline JP"],"funding":["Insulet Corporation"],"pubmed_abstract":["<h4>Aims</h4>Beyond their glycaemic benefits, automated insulin delivery (AID) systems can provide psychosocial benefits for people with type 1 diabetes (T1D) and improve quality of life. In this study, we evaluated psychosocial outcomes in adults with T1D using the tubeless Omnipod® 5 AID System compared with sensor augmented pump (SAP) therapy.<h4>Materials and methods</h4>As part of a 13-week multicentre, parallel-group, randomised controlled trial comparing intervention (tubeless AID) and control (SAP) groups (2:1), adults aged 18-70 years with T1D completed validated psychosocial questionnaires assessing health-related quality of life (European Quality of Life 5 Dimensions 3 Level Version [EQ-5D-3L] index score and visual analogue scale [VAS]), the impact of diabetes on quality of lif"],"journal":["Diabetes, obesity & metabolism"],"pagination":["2227-2236"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12916430"],"repository":["biostudies-literature"],"pubmed_title":["Psychosocial outcomes among adults with type 1 diabetes using a tubeless automated insulin delivery system compared with sensor augmented pump therapy: A randomised, parallel-group clinical trial sub-study."],"pmcid":["PMC12916430"],"pubmed_authors":["Suh B","Downs A","Hami R","Oliver D","Shelton N","Salhin A","Dong X","Laffel LM","Kravarusic J","Wodetzki D","Isganaitis E","Siadoua M","Hughes M","Hernandez J","Norlander L","Bloks T","Shoemaker R","Aleppo G","Herrmann S","Hirchak C","Thivolet C","Vidal-Trecan T","Averkiou X","Penfornisy A","Castorino K","Riveline JP","Lewis M","Thorsell A","Huyett LM","Brown SA","Penfornis A","Farret A","Ambler-Osborn L","Walker S","Vienneau T","Renard E","Maxson A","Ramon V","Tabb C","Herndon C","Beatson C","Christie K","Akturk HK","Ly TT","Weinstock RS","Guevara E","Rosas K","Dunn E","Lal RA","Dumais B","Johnson J","Volkening L","Beltran S","Kipnes MS","Ryan T","Penn S","Kivilaid K","Fimbel SV","Hirsch IB","Stumpf M","Alix C","Blanscet H","Mulvey S","Mandava P","Qamar L","Miller KM","Villard O","Church MM","Shah VN","Buckingham BA","Gautier JF","Bellili D","Malik F","Pour FM","OP5‐003 Research Group","Petit C","Stone SL","Julia JB","Fuller M","Doolan J","Bode BW","Kingman R","Goroza E","Al Masri M","Bzdick S","Conroy LR","Reed D","Turcotte C","Hsu L","Moore A","Joseph H","Ownby J","Wilby C","Potier C"],"additional_accession":[]},"is_claimable":false,"name":"Psychosocial outcomes among adults with type 1 diabetes using a tubeless automated insulin delivery system compared with sensor augmented pump therapy: A randomised, parallel-group clinical trial sub-study.","description":"<h4>Aims</h4>Beyond their glycaemic benefits, automated insulin delivery (AID) systems can provide psychosocial benefits for people with type 1 diabetes (T1D) and improve quality of life. In this study, we evaluated psychosocial outcomes in adults with T1D using the tubeless Omnipod® 5 AID System compared with sensor augmented pump (SAP) therapy.<h4>Materials and methods</h4>As part of a 13-week multicentre, parallel-group, randomised controlled trial comparing intervention (tubeless AID) and control (SAP) groups (2:1), adults aged 18-70 years with T1D completed validated psychosocial questionnaires assessing health-related quality of life (European Quality of Life 5 Dimensions 3 Level Version [EQ-5D-3L] index score and visual analogue scale [VAS]), the impact of diabetes on quality of lif","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Mar","modification":"2026-07-16T06:40:46.696Z","creation":"2026-07-09T10:41:06.335Z"},"accession":"S-EPMC12916430","cross_references":{"pubmed":["41508715"],"doi":["10.1111/dom.70416"]}}